Doric Nimrod Air One Share Price (DNA)

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Doric Nimrod Air One Limited LSE:DNA London Ordinary Share GG00B4MF3899 ORD PRF SHS NPV
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 94.00p 0 01:00:00
Bid Price Offer Price High Price Low Price Open Price
92.00p 96.00p 94.00p 94.00p 94.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 12.04 28.37 3.3 39.9
Related Shares
Scottish Mortgage Invest... (SMT), Etfs Phy Pm B � (PHPP), Energiser Investments (ENGI), Tiger Resource (TIR)

Doric Nimrod Air One (DNA) Latest News

Doric Nimrod Air One News

Date Time Source Headline
14/2/201918:01DJNNimrod Capital Sees Future for A380-Leasing Despite Discontinuation
14/2/201916:40UKREGDoric Nimrod Air One Limited Statement re AIRBUS A380 UPDATE
14/11/201816:59UKREGDoric Nimrod Air One Limited Half-year Report
08/11/201816:42UKREGDoric Nimrod Air One Limited Result of AGM
11/10/201818:34UKREGDoric Nimrod Air One Limited Notice of AGM
11/7/201817:25UKREGDoric Nimrod Air One Limited Quarterly Report
11/7/201817:24UKREGDoric Nimrod Air One Limited Dividend Declaration
11/7/201817:23UKREGDoric Nimrod Air One Limited Annual Financial Report
More Doric Nimrod Air One News
Doric Nimrod Air One Takeover Rumours

Doric Nimrod Air One (DNA) Share Charts

1 Year Doric Nimrod Air One Chart

1 Year Doric Nimrod Air One Chart

1 Month Doric Nimrod Air One Chart

1 Month Doric Nimrod Air One Chart

Intraday Doric Nimrod Air One Chart

Intraday Doric Nimrod Air One Chart

Doric Nimrod Air One (DNA) Discussions and Chat

Doric Nimrod Air One Forums and Chat

Date Time Title Posts
18/9/201808:56Doric Nimrod Air One28
22/2/201812:03DNA & FORENSIC SCIENCE165
13/11/200900:14DNA DATABASE-
06/11/200816:44Genographic Project DNA Genetics National Geographic-

Add a New Thread

Doric Nimrod Air One (DNA) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Doric Nimrod Air One trades in real-time

Doric Nimrod Air One (DNA) Top Chat Posts

DateSubject
19/5/2019
09:20		Doric Nimrod Air One Daily Update: Doric Nimrod Air One Limited is listed in the Equity Investment Instruments sector of the London Stock Exchange with ticker DNA. The last closing price for Doric Nimrod Air One was 94p.
Doric Nimrod Air One Limited has a 4 week average price of 93.50p and a 12 week average price of 92p.
The 1 year high share price is 116p while the 1 year low share price is currently 92p.
There are currently 42,450,000 shares in issue and the average daily traded volume is 15,481 shares. The market capitalisation of Doric Nimrod Air One Limited is £39,903,000.
Read Full Thread
Reply
15/4/2009
09:19		ariane: Genentech Executives Start Leaving in Wake of Roche Acquisition Share | Email | Print | A A A By Rob Waters April 15 (Bloomberg) -- Top leaders of Genentech Inc., the biotechnology company acquired by Roche Holding AG for $46.8 billion, will leave the company as part of personnel moves that put an executive of the Swiss drugmaker at the helm. Arthur Levinson, 59, Genentech's chief executive officer since 1995, will become chairman of its board, steering efforts to combine the two companies, Roche said yesterday in a statement. Other key executives, including product development chief Susan Desmond-Hellmann, will leave by mid-year. Genentech employees become eligible to receive retention bonuses July 1 under a program approved last August. Pascal Soriot, who runs commercial operations for Roche's drug division, will become Genentech's chief executive officer responsible for U.S.-based pharmaceutical operations. Roche officials also will take over from departing Genentech employees as chief financial and compliance officers. The changes mark the beginning of the company's transformation, said Stephen Burrill, a venture capitalist who invests in biotechnology companies. "By and large, the Genentech leadership will move on, staying as long as their golden handcuffs require them to," Burrill said yesterday in a telephone interview. "The spirit of entrepreneurship won't be the same. People who were excited by entrepreneurship will find new homes and those that are comfortable with a large corporate structure will stay." Pioneering Technique Genentech was founded in 1976 by Herbert Boyer, a genetic engineering researcher at the University of California, San Francisco, and Robert Swanson, then a 29-year-old venture capitalist. Boyer and Stanford University scientist Stanley Cohen pioneered the technique that allows scientists to insert genes from one organism into another, laying the foundations for antibody-based drugs, bioengineered crops and gene therapy. In the ensuing decades, South San Francisco, California- based Genentech made the first human protein by splicing genes into E. coli bacteria and later synthesized human insulin and human growth hormone. The company went public in 1980 in an initial offering that raised $35 million, and saw the share price rise to $88 from $35 in less than an hour. Basel, Switzerland-based Roche, the world's largest drugmaker by market value, held a stake in South San Francisco, California-based Genentech for almost 20 years and controlled 56 percent of the biotechnology company's shares before starting its acquisition bid in July. Roche sought the takeover to boost income from top-selling cancer medicines such as Avastin. Roche completed the transaction on March 26. 'Sad Day' "It is a sad day for me and many others," Myrtle Potter, former president of commercial operations at Genentech, said in an e-mail. Potter left the company in 2005. Levinson will be nominated for a seat on Roche's board of directors at its next shareholder meeting in 2010, according to the Roche statement. He and Soriot will lead efforts to integrate the companies, Roche said. Soriot joined Roche in 2006 and was previously a U.S.-based executive with Sanofi-Aventis SA, the French drugmaker, said Geoff Teeter, a Genentech spokesman. The management changes take effect May 1, Roche said in its statement. Desmond-Hellman, 51, will advise the company after her departure as a member of the Genentech Scientific Resource Board. By staying until June 30, she will be eligible for a retention bonus of $4.59 million, Genentech said in an Aug. 21, 2008, filing with the U.S. Securities and Exchange Commission. David A. Ebersman, the departing executive vice president and chief financial officer, could receive $2.73 million under the retention plan, according to the filing. Desmond-Hellman's departure is "the beginning of senior executive departures and it's symbolic in that context," Burrill said. "She's a hot rock and will be very desired by a lot of other companies to take a leadership position." To contact the reporter on this story: Rob Waters in San Francisco at rwaters5@bloomberg.net. Last Updated: April 15, 2009 00:01 EDT
Read Full Thread
Follow
Reply
10/3/2009
10:18		waldron: Roche Doesn't Consider $112/Share Realistic For Genentech -Chairman BASEL -(Dow Jones)- Roche Holding AG (ROG.VX) Chairman Franz Humer said Tuesday the Swiss drugmaker doesn't consider as realistic the $112 a share price for Genentech Inc. (DNA) proposed by directors of the biotechnology company as a condition to agree to a takeover. Humer was speaking to shareholders at the company's annual general meeting in Basel, Switzerland. On Friday, Roche increased its offer to buy the roughly 44% of U.S. biotechnology company Genentech Inc. (DNA) it doesn't already own, in a deal worth around $45.7 billion. The price reflects a price of $93 per share. On Monday, the Wall Street Journal reported that the two companies are close to agreeing a deal at a price of $95 per share. The bid was again rejected as too low by Genentech's special committee of independent board members. But Humer said assumptions on which the committee bases its asking price are flawed. "We feel the price proposed by the special committee, $112 per share, isn't based on realistic assumptions," Humer said. Overly optimistic assumptions include, the committee's view about the potential impact from follow-on biologics, or generic copies of biotechnology drugs that lost patent protection. The committee also overestimates productivity gains and the potential increase in success rates in research and development, he added. Roche also considers the committee's view on the market potential of cancer drug Avastin in new uses, and possibilities for price increases in the U.S. market as either inadequate or overly optimistic, Humer said. Roche has raised close to $40 billion through various bond offerings to finance the deal. Given that the Swiss drugmaker commands around $7 billion in liquid funds already, financing of the deal looks secure, analysts say. Company Web site: www.roche.com -By Anita Greil, Dow Jones Newswires; +41 43 443 8044 ; anita.greil@dowjones.com
Read Full Thread
Follow
Reply
23/1/2009
17:22		waldron: Roche Faces Big Decision On Genentech Bid As Key Data Loom By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK -(Dow Jones)- Roche Holding AG (RHHBY) has consistently reiterated its devotion to buying the 44% of Genentech Inc. (DNA) that it doesn't already own, but the potential early arrival of a key study means the company may have to decide its next step soon. If the Swiss drugmaker waits for the data regarding Genentech's flagship cancer drug Avastin, possibly coming in mid-April, and the results are considered a success, Roche risks paying significantly more than the already rejected offer of $89 a share. If the study fails, it could pay less. Roche can also decide not to take the gamble, but it needs to move soon to cut a deal with Genentech and get financing amid tight credit markets. "I honestly think it could be any day now," Robert Baird & Co. analyst Chris Raymond said, referring to his expectations for a higher bid. If a deal is reached soon, Wall Street generally expects it to be higher than $95 a share. A successful study could drive Genentech's value above $100, excluding any premium from a Roche offer, while its failure may actually bring Roche to lower its rejected offer from July. Shares of Genentech, recently at $83.94, have traded below the offer price since late September, after hitting a high of $99.14. The drop reflects doubts about Roche's ability to close the deal amid tight credit markets, rather than concerns related to the forthcoming study. Roche shares recently fell 1.22% to $36.30. Neither Roche nor Genentech would comment on the acquisition offer. Genentech's next few years will likely be driven by Avastin, which is approved to treat advanced breast, lung and colorectal cancer and had 2008 sales of $2.69 billion. The drug's future trajectory will be determined by its potential use in the adjuvant setting - when it is administered after cancer is surgically removed.Currently, Avastin is only used on cancer that has spread beyond its original site. Its use as an earlier treatment could add billions of dollars in sales, and the so-called C-08 study will be the first view of the drug's adjuvant use in colorectal cancer. The trial is being run by a third-party cooperative group and Genentech had expected the data to come in the middle of the year, but earlier this week disclosed it could be as early as mid-April. Most Wall Street analysts see colorectal adjuvant usage adding at least $1 billion in annual sales. Lazard Capital Markets recently estimated that adjuvant usage in breast, lung and colorectal cancer could ultimately bring more than $9 billion in additional annual sales. Genentech has acknowledged the importance of Avastin's adjuvant use to the drug's growth over the next three to five years, but also asserts that approval isn't essential. "I think people get understandably focused or even obsessed by the adjuvant result," said Ian Clark, executive vice president of commercial operations, in an interview last week. "I'm confident that we can continue to grow the business even without a positive adjuvant study." Back To The Wall The shorter timeline for the data's release puts Roche in the position of either raising its bid before such monumental data, or waiting to see the results and riding the inevitable shift in the value of the Genentech. "It's my view that both parties are incentivized to get this thing done before the data comes out," Raymond said. Roche recently said that the deal is on track, despite the ongoing financial crisis, and that it always expected the process to take a year from the original bid, according to The Wall Street Journal. But some believe that Roche always intended to close the deal before the announcement of the C-08 results, and now the timing shift has backed it into a corner. Some speculate that Roche will make a bid before releasing 2008 financial results on Feb. 4. Besides getting the approval of Genentech's independent board and from shareholders, Roche will have to line up financing amid the financial crisis. The deal would be huge: The original $44 billion offer goes up $500 million for every dollar added to the original $89-per-share bid. Analysts expect a deal somewhere above $95 per share, and many are aiming closer to $105 a share. The price to Roche is also higher as the U.S. dollar has strengthened against the Swiss Franc, adding 14% to the original bid in July, when Roche cited the weak dollar as a motivating factor for the deal. Rolling The Dice If Roche either can't get the deal done prior to the data, or it decides to take its chances, it is sure to provide a wild ride for Genentech shareholders. "If data are positive and Roche has not closed the deal, we suspect the price of Genentech will become too expensive for Roche to finance," said Morgan Stanley analyst Steven Harr. But success is not guaranteed, and negative data will likely have the opposite effect, possibly making Roche's previous $89-a-share offer look too expensive. "I don't know where Roche would come out in valuing Genentech at that point, but definitely it would be below $89," said RBC Capital Markets analyst Jason Kantor, noting that the original offer won't necessarily be on the negotiating table after the C-08 data because the independent board already rejected it. Any deal before the data release will likely include a large breakup fee or some other mechanism to avoid a renegotiation after the news comes out. In the meantime, until the data, most on Wall Street don't expect major changes to Genentech's share price as most investors are well aware of the risks regarding the deal and the study. "You are kind of crazy to own the stock if you don't think that the data is going to be positive," Kantor said. -By Thomas Gryta, Dow Jones Newswires; 201-938-2053; thomas.gryta@dowjones.com
Read Full Thread
Follow
Reply
14/10/2005
09:27		ariane: Leu Ups Roche To Buy, Lifts Target To CHF210 Friday, October 14, 2005 3:37:25 AM ET Dow Jones Newswires 0718 GMT [Dow Jones] Bank Leu raises Roche (RHHBY) to buy from hold, target to CHF210 from CHF186 following strong 3Q from Genentech (DNA) and ahead of Roche's own 9 months results. "Looking into 2006 we see ample clinical and regulatory newsflow that is expected to drive the share price." Roche +0.1% at CHF184.80. (HJS) http://www.newratings.com/analyst_news/article_1063099.html
Read Full Thread
Follow
Reply
Doric Nimrod Air One share price data is direct from the London Stock Exchange
Your Recent History
LSE
DNA
Doric Nimr..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190520 00:31:47